DocWire News Editors

DocwireNews

The benefit of rivaroxaban monotherapy for patients with atrial fibrillation (AF) after coronary stenting was dependent on the duration of time from stenting, according to data from a secondary analysis of the AFIRE trial presented at the American Heart Association Scientific Session 2020.&ldquo;Although there was a numerical excess of coronary events within 2 years from stenting, the benefit of monotherapy for the safety endpoint and net adverse clinical events support the overall benefit of rivaroxaban monotherapy in patients with AF after 1 year of coronary stenting,&rdquo; said presented Tetsuya Matoba, MD, PhD, FAHA, of Kyushu University, Japan.AFIRE assessed antithrombotic therapy in 2,215 patients with AF and stable coronary artery disease. In the primary analysis of the study, rivaroxaban was noninferior to combination therapy with rivaroxaban plus an anti-platelet therapy (APT) for the composite endpoint of stroke, systemic embolism, myocardial infarction, unstable angina requiring revascularization, or death from any cause; monotherapy was superior for the safety endpoint of major bleeding.This analysis was conducted due to concerns about thrombotic events due to cessation of APT in a subgroup of 1,444 patients who had undergone coronary stenting more than 1 year prior. The researchers looked at benefits of rivaroxaban in patients less than 2 years from stenting (n= 419; 29%) and compared them with patients 2 years or more from stenting (n=1,025; 71%). For patients less than 2 years from stenting there was 10 first-generation drug eluting stents (DES) and 381 second generation DES. For patients 2 years or further from stenting it was 213 and 401, respectively.This analysis examined coronary events &ndash; a composite of fatal and non-fatal MI, unstable angina, coronary revascularization, or stent thrombosis &ndash; and net adverse clinical events (NACE) &ndash; a composite of stroke, MI, death from any cause, or major bleeding.The cumulative incidence of the primary efficacy endpoint was 5.15% for monotherapy compared with 3.99% for combination therapy (HR=1.29; 95% CI, 0.66-2.50; P=0.453). In patients 2 or more years from stenting the cumulative incidence was 3.71% for monotherapy compared with 6.67% for combination therapy (HR=0.56; 95% CI, 0.37-0.84; P=.004).Remarkably there was no significant excess of coronary events with monotherapy in patients less than 2 years from stenting, Dr. Matoba said. The cumulative incidence of coronary events for patients within 2 years of stenting was 3.2% for monotherapy compared with 1.33% for combination therapy (HR=2.39; 95% CI, 0.85-6.71; P=.087). In contrast, for patients 2 or more years from stenting the cumulative incidence of coronary events was 2.31% for monotherapy compared with 2.47% for combination therapy (HR=0.94; 95% CI, 0.53-1.65; P=.825).For the primary safety endpoint, the benefit of monotherapy was consistent. The HR of monotherapy was 0.72 for patients less than 2 years from stenting. For patients 2 or more years from stenting the HR was 0.48 with a P value of 0.019.Finally, the HRs for the NACE was 0.71 for patients less than 2 years (P=0.284) and 0.54 for patients two or more years from stenting (P=.002).

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Rivaroxaban Monotherapy Safe for AF After Coronary Stenting

AHA Scientific Sessions 2020

The benefit of rivaroxaban monotherapy for patients with atrial fibrillation (AF) after coronary stenting was dependent on the duration of time from stenting, according to ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe